Stock listing
Stuttgart:S2P Simcere Pharmaceutical Group Limited Aktie
German listing (Stuttgart) of Simcere Pharmaceutical Group Limited · home listing HKEX:2096
Follow Simcere Pharmaceutical Group Limited into a list and get an email when it puts out news.
Home listing price · HKEX:2096
$10.19 HKD -0.23 (-2.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, HKEX:2096
- Day range
- $10.14 – $10.42 HKDNov 20, 2026
- Volume
- 4.46M sharesNov 20, 2026
- Market cap
- $26.05B HKDAt the close on Nov 20, 2026 · price × 2.56B shares outstanding
- 52-week range
- $9.07 – $14.34 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $54.70M HKDMedian day 4.48M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:2096 · Home | $10.19 HKD | -0.23 (-2.2%) | 4,461,784 | $10.36 | $10.42 | $10.14 | $10.42 | Close on Nov 20, 2026 |
| Frankfurt:S2P | €1.19 EUR | +0.01 (+0.8%) | — | €1.19 | €1.19 | €1.19 | €1.18 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:2096 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $10.19 | -0.23 | -2.2% | $10.36 | $10.42 | $10.14 | 4,461,784 | |
| $10.42 | -0.08 | -0.8% | $10.40 | $10.58 | $10.34 | 3,989,407 | |
| $10.50 | -0.05 | -0.5% | $10.67 | $10.67 | $10.33 | 3,883,000 | |
| $10.55 | -0.03 | -0.3% | $10.49 | $10.63 | $10.42 | 3,077,000 | |
| $10.58 | -0.31 | -2.8% | $10.71 | $10.85 | $10.51 | 2,365,537 | |
| $10.89 | -0.02 | -0.2% | $10.81 | $11.03 | $10.77 | 2,500,600 | |
| $10.91 | -0.12 | -1.1% | $11.15 | $11.15 | $10.71 | 3,201,000 | |
| $11.03 | -0.17 | -1.5% | $11.20 | $11.33 | $10.99 | 2,523,540 | |
| $11.20 | +0.11 | +1.0% | $11.30 | $11.38 | $11.13 | 2,085,603 | |
| $11.09 | -0.08 | -0.7% | $11.00 | $11.32 | $10.87 | 4,433,060 | |
| $11.17 | +0.40 | +3.7% | $10.84 | $11.29 | $10.84 | 5,637,000 | |
| $10.77 | +0.59 | +5.8% | $10.20 | $10.82 | $10.17 | 8,272,519 | |
| $10.18 | +0.16 | +1.6% | $10.11 | $10.22 | $9.915 | 8,603,519 | |
| $10.02 | -0.12 | -1.2% | $10.07 | $10.23 | $9.86 | 8,895,000 | |
| $10.14 | -0.24 | -2.3% | $10.23 | $10.44 | $10.04 | 4,494,000 | |
| $10.38 | +0.07 | +0.7% | $10.30 | $10.48 | $10.23 | 4,208,000 | |
| $10.31 | +0.12 | +1.2% | $10.21 | $10.46 | $10.19 | 9,611,610 | |
| $10.19 | -0.32 | -3.0% | $10.44 | $10.57 | $10.08 | 9,373,796 | |
| $10.51 | -0.18 | -1.7% | $10.84 | $10.98 | $10.47 | 3,312,000 | |
| $10.69 | +0.31 | +3.0% | $10.33 | $10.82 | $10.15 | 6,084,000 | |
| $10.38 | -0.49 | -4.5% | $10.68 | $10.86 | $10.33 | 5,828,700 | |
| $10.87 | -0.07 | -0.6% | $11.07 | $11.10 | $10.83 | 2,100,000 | |
| $10.94 | -0.08 | -0.7% | $11.02 | $11.20 | $10.86 | 2,445,000 | |
| $11.02 | +0.19 | +1.8% | $10.85 | $11.29 | $10.85 | 5,801,000 | |
| $10.83 | -0.05 | -0.5% | $10.87 | $11.05 | $10.70 | 3,387,000 | |
| $10.88 | +0.16 | +1.5% | $10.80 | $10.99 | $10.56 | 2,487,000 | |
| $10.72 | -0.18 | -1.7% | $10.90 | $10.90 | $10.50 | 5,233,215 | |
| $10.90 | +0.01 | +0.1% | $11.04 | $11.05 | $10.82 | 1,771,000 | |
| $10.89 | -0.09 | -0.8% | $10.92 | $11.10 | $10.62 | 4,810,000 | |
| $10.98 | -0.42 | -3.7% | $11.50 | $11.63 | $10.98 | 4,765,000 | |
| $11.40 | -0.13 | -1.1% | $11.50 | $11.51 | $11.25 | 1,281,340 | |
| $11.53 | +0.12 | +1.1% | $11.64 | $11.64 | $11.50 | 983,718 | |
| $11.41 | -0.05 | -0.4% | $11.27 | $11.44 | $11.11 | 1,992,000 | |
| $11.46 | -0.39 | -3.3% | $11.80 | $11.80 | $11.21 | 2,432,000 | |
| $11.85 | +0.48 | +4.2% | $11.25 | $11.89 | $11.25 | 8,006,844 | |
| $11.37 | +0.13 | +1.2% | $11.19 | $11.49 | $11.19 | 3,446,000 | |
| $11.24 | +0.05 | +0.4% | $11.18 | $11.48 | $11.18 | 2,795,000 | |
| $11.19 | -0.20 | -1.8% | $11.30 | $11.30 | $11.05 | 506,000 | |
| $11.39 | -0.28 | -2.4% | $11.61 | $11.71 | $11.28 | 3,584,000 | |
| $11.67 | +0.07 | +0.6% | $11.61 | $11.73 | $11.47 | 2,776,000 | |
| $11.60 | -0.01 | -0.1% | $11.75 | $11.75 | $11.35 | 4,663,989 | |
| $11.61 | +0.44 | +3.9% | $11.30 | $11.82 | $11.27 | 5,801,000 | |
| $11.17 | -0.10 | -0.9% | $11.07 | $11.49 | $11.07 | 12,393,000 | |
| $11.27 | +0.10 | +0.9% | $11.06 | $11.36 | $11.02 | 2,608,472 | |
| $11.17 | -0.08 | -0.7% | $11.11 | $11.25 | $11.06 | 2,716,666 | |
| $11.25 | -0.14 | -1.2% | $11.38 | $11.50 | $11.16 | 2,323,000 | |
| $11.39 | +0.34 | +3.1% | $11.07 | $11.44 | $10.92 | 7,211,232 | |
| $11.05 | -0.17 | -1.5% | $11.17 | $11.20 | $10.93 | 7,763,000 | |
| $11.22 | -0.35 | -3.0% | $11.57 | $11.57 | $11.13 | 5,096,000 | |
| $11.57 | -0.06 | -0.5% | $11.64 | $11.68 | $11.46 | 3,367,000 | |
| $11.63 | +0.05 | +0.4% | $11.60 | $11.76 | $11.46 | 2,111,000 | |
| $11.58 | -0.05 | -0.4% | $11.70 | $11.74 | $11.42 | 4,869,000 | |
| $11.63 | -0.14 | -1.2% | $11.77 | $12.01 | $11.59 | 4,919,000 | |
| $11.77 | -0.06 | -0.5% | $11.88 | $11.90 | $11.47 | 6,869,000 | |
| $11.83 | +0.84 | +7.6% | $11.52 | $11.87 | $11.15 | 14,737,000 | |
| $10.99 | -0.11 | -1.0% | $11.10 | $11.10 | $10.96 | 4,355,000 | |
| $11.10 | -0.20 | -1.8% | $11.31 | $11.35 | $11.02 | 7,703,000 | |
| $11.30 | -0.21 | -1.8% | $11.51 | $11.51 | $11.27 | 4,726,000 | |
| $11.51 | -0.09 | -0.8% | $11.60 | $11.60 | $11.33 | 4,617,000 | |
| $11.60 | +0.07 | +0.6% | $11.59 | $11.79 | $11.53 | 5,882,000 | |
| $11.53 | -0.07 | -0.6% | $11.69 | $11.69 | $11.34 | 5,952,643 | |
| $11.60 | -0.48 | -4.0% | $12.18 | $12.29 | $11.52 | 5,191,643 | |
| $12.08 | -0.12 | -1.0% | $12.40 | $12.40 | $11.87 | 7,444,000 | |
| $12.20 | +0.03 | +0.2% | $12.69 | $12.82 | $12.13 | 14,074,000 |
- Ticker
- Stuttgart:S2P
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Nov 20, 2026
Next Day Disclosure Return
Latest news
Voluntary announcement - the clinical trial approval for SIM0712 (STAT6) issued by the national medical products administration
Nov 16, 2026
Closed $10.50 (-0.5%) on Nov 17, 2026
Voluntary announcement - inclusion of Sanbexin sublingual tablets into the new national reimbursement drug list
Nov 15, 2026
Closed $10.55 (-0.3%) on Nov 16, 2026
Voluntary announcement - the clinical trial approval for SIM0725 (CD122) issued by the national medical products administration
Nov 10, 2026
Closed $10.91 (-1.1%) on Nov 11, 2026
Voluntary announcement - the clinical trial approval for SIM0709 (TL1A/il-23P19 bispecific antibody) issued by the german regulatory authority and ethics committee
Nov 9, 2026
Closed $11.03 (-1.5%) on Nov 10, 2026
Voluntary announcement - new drug application (nda) of zemprocitinib for the treatment of rheumatoid arthritis was accepted by the national medical products administration
Nov 5, 2026
Closed $11.09 (-0.7%) on Nov 6, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Nov 4, 2026
Closed $11.17 (+3.7%) on Nov 5, 2026
Simcere Pharmaceutical Group Limited on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 26 in the last 12 months · 42 in all · newest Nov 20, 2026 · oldest 2021
Where Simcere Pharmaceutical Group Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:2096 先聲藥業 · Home listing | HKEX | Hong Kong | HKD |
| OTC:SMHGF | OTC | United States | USD |
| LS Exchange:A2QD9S | LS Exchange | Germany | EUR |
| gettex:S2P | gettex | Germany | EUR |
| Tradegate:S2P | Tradegate | Germany | EUR |
| Dusseldorf:S2P | Dusseldorf | Germany | EUR |
| Frankfurt:S2P | Frankfurt | Germany | EUR |
| Munich:S2P | Munich | Germany | EUR |
| Stuttgart:S2P · This page | Stuttgart | Germany | EUR |
| Lang & Schwarz:A2QD9S | Lang & Schwarz | Germany | EUR |
Valuation
P/E 16.5× against a median of 22.3×: 3rd lowest of 11 Pharmaceuticals companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $24.15B HKD
- P/E
- 16.5×
- EV/sales
- 2.7×
- EV/EBITDA
- 10.6×
- Price/book
- 2.4×
- Gross margin
- 81.6%
- Operating margin
- 20.1%
- Net margin
- 17.4%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Simcere Pharmaceutical Group Limited · HKEX:2096 | US$3.32B | US$3.08B | 16.5× | 2.7× | 10.6× | 2.4× | 17.4% | 0.3× | n/a |
| China Resources Pharmaceutical Group Ltd. · HKEX:3320 | US$3.51B | US$14.02B | 5.2× | 0.3× | 5.1× | 0.4× | 1.5% | 1.9× | n/a |
| Zhejiang Huahai Pharmaceutical Co., Ltd. Class A · SSE:600521 | US$3.49B | US$3.65B | 24.6× | 2.5× | n/a | 2.3× | 9.8% | 0.3× | n/a |
| Orion Oyj Class A · OMXHEX:ORNAV | US$3.42B | US$3.40B | 4.7× | 1.4× | 3.5× | 2.2× | 30.3% | 0.1× | n/a |
| Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A · SZSE:002262 | US$3.41B | US$2.79B | 20.8× | 3.0× | n/a | 2.6× | 17.7% | 0.0× | n/a |
| Beijing Tiantan Biological Products Corporation Limited Class A · SSE:600161 | US$3.39B | US$3.10B | 32.3× | 3.7× | n/a | 1.9× | 12.6% | 0.0× | n/a |
| Arcutis Biotherapeutics, Inc. · NASDAQ:ARQT | US$3.33B | US$3.18B | 111× | 6.3× | 85.1× | 13.7× | 5.9% | 0.5× | 1.38 |
| Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A · SSE:600329 | US$3.20B | US$3.00B | 23.9× | 4.3× | n/a | 3.4× | 19.2% | 0.0× | n/a |
| Virbac SA · EURONEXT:VIRP | US$3.15B | US$3.35B | 19.0× | 2.1× | 11.0× | 2.4× | 10.3% | 0.3× | n/a |
| Tasly Pharmaceutical Group Co. Ltd. Class A · SSE:600535 | US$3.14B | US$2.60B | 17.1× | 2.2× | n/a | 1.6× | 15.3% | 0.0× | n/a |
| Hualan Biological Engineering Inc. Class A · SZSE:002007 | US$3.13B | US$2.62B | 35.6× | 4.6× | n/a | 2.0× | 15.4% | 0.0× | n/a |
| Median of the others | US$3.36B | US$3.14B | 22.3× | 2.8× | 8.1× | 2.3× | 14.0% | 0.1× | 1.38 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 19.49 HKD · Analysts' mean
- EPS, year to Dec 2026
- 0.69 · 2 analysts
- Revenue, year to Dec 2026
- 1.52B · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Tang Renhong | Non-Executive Director of Simcere, Chairman of the Board and CEO of Simcere Zaiming |
| Shen Jun | Chief Financial Officer and Secretary of the Board of Simcere Zaiming |
| Wan Yushan | Executive Director and Chief Financial Officer |
| Felix Wang | Senior Vice President |
| Goh Aik Han | Senior Vice President, Chief Medical Officer |
| Tamas Oravecz | SVP & CSO of Simcere Zaiming |
| Wang Xi | Executive Director and Vice President |
| Wang Yongyu | Senior Vice President and Chief Medical Officer of Simcere Zaiming |
| Zhou Gaobo | Chief Investment Officer |
Board
| Director | Role |
|---|---|
| Ren Jinsheng | Chairman of Simcere Pharmaceutical Group |
| Tang Renhong | Non-Executive Director of Simcere, Chairman of the Board and CEO of Simcere Zaiming |
| Wan Yushan | Executive Director and Chief Financial Officer |
| Wang Xi | Executive Director and Vice President |
Events
- Next results
- Mar 22, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Aug 21, 2025 · Before open | +3.1% |
| Quarter to Mar 31, 2025 | Apr 28, 2025 | +2.3% |
| Q4 2024 | Mar 24, 2025 · Before open | +0.5% |
| Q3 2024 | Nov 18, 2024 | −3.4% |
| Q2 2024 | Aug 21, 2024 | −4.9% |
| Q1 2024 | Jun 14, 2024 · Before open | −0.5% |
| Q4 2023 | Mar 20, 2024 | +3.6% |
| Q3 2023 | Nov 16, 2023 | −2.1% |
| Q2 2023 | Aug 21, 2023 · Before open | +0.2% |
| Q1 2023 | May 11, 2023 | −3.1% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2022 | Mar 31, 2023 · Before open | +0.7% |
| Q3 2022 | Nov 17, 2022 | +4.5% |
| Q2 2022 | Aug 31, 2022 · Before open | −0.3% |
| Q1 2022 | May 12, 2022 | +19.1% |
| Q4 2021 | Mar 24, 2022 · Before open | +0.9% |
| Q3 2021 | Nov 11, 2021 | −3.7% |
| Q2 2021 | Aug 26, 2021 · Before open | −2.7% |
| Q1 2021 | May 6, 2021 | −1.8% |
| Q4 2020 | Mar 25, 2021 · Before open | −1.3% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.73B | 6.64B | 6.61B | 6.32B | 5.00B | 4.51B | 5.04B | 4.51B | 3.87B | 2.08B |
| Cost of revenue | 1.42B | 1.31B | 1.62B | 1.32B | 1.08B | 899.9M | 888.5M | 771.2M | 586.3M | 361.1M |
| Gross profit | 6.31B | 5.32B | 4.98B | 5.00B | 3.92B | 3.61B | 4.15B | 3.74B | 3.28B | 1.72B |
| Research and development | 1.56B | 1.41B | 1.56B | 1.73B | 1.42B | 1.14B | 716.4M | 447.1M | 212.3M | 228.7M |
| Selling, general and administrative | 599.3M | 526.0M | 487.8M | 444.2M | 382.5M | 411.5M | 142.6M | 129.7M | 126.9M | 256.0M |
| Operating income | 1.56B | 848.0M | 711.8M | 862.5M | 1.45B | 926.8M | 1.17B | 941.9M | 530.6M | 96.4M |
| Depreciation and amortization | 380.8M | 337.9M | 309.6M | 283.6M | 251.8M | 227.4M | 162.5M | 120.0M | 104.1M | 131.6M |
| EBITDA | 1.94B | 1.19B | 1.02B | 1.15B | 1.70B | 1.15B | 1.33B | 1.06B | 634.7M | 228.0M |
| Interest expense | 95.8M | 69.6M | 34.6M | 34.4M | 70.8M | 133.7M | 116.0M | 47.5M | 58.4M | 0 |
| Income before tax | 1.51B | 819.9M | 740.0M | 888.2M | 1.40B | 805.1M | 1.08B | 929.0M | 497.3M | -20.0M |
| Income tax | 170.3M | 86.7M | 26.1M | -40.5M | -97.1M | 140.8M | 78.2M | 195.4M | 146.9M | 5.58M |
| Net income | 1.34B | 733.2M | 714.8M | 930.9M | 1.51B | 669.5M | 1.00B | 733.7M | 350.4M | 57.0M |
| Earnings per share, basic | 0.54 | 0.29 | 0.27 | 0.36 | 0.58 | 0.26 | 0.39 | 0.28 | 0.13 | 0.53 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.55B | 1.94B | 2.01B | 1.66B | 973.1M | 3.27B | 354.8M | 1.19B | 572.6M | 178.2M |
| Short-term investments | 65.6M | 10.0M | 11.1M | 964.2M | 1.21B | 3.63M | 547.0M | 263.3M | 509.1M | |
| Receivables | 2.96B | 2.71B | 2.64B | 2.50B | 2.40B | 1.87B | 1.34B | 1.65B | 1.24B | 1.09B |
| Inventory | 589.7M | 593.6M | 770.1M | 304.8M | 235.2M | 311.1M | 248.2M | 265.6M | 218.3M | 120.9M |
| Current assets | 7.39B | 5.47B | 5.64B | 5.45B | 4.98B | 6.47B | 2.90B | 3.67B | 2.78B | 1.74B |
| Property, plant and equipment | 2.53B | 2.27B | 2.17B | 2.14B | 1.93B | 2.13B | 1.87B | 1.38B | 1.18B | 840.6M |
| Goodwill | 142.5M | 142.5M | 142.5M | 172.8M | 172.8M | 172.8M | 142.5M | 142.5M | 142.5M | 284.6M |
| Total assets | 14.7B | 11.5B | 10.9B | 10.8B | 10.2B | 10.9B | 6.77B | 6.34B | 5.20B | 3.37B |
| Accounts payable | 240.6M | 275.7M | 317.2M | 335.4M | 324.0M | 242.1M | 254.9M | 307.6M | 215.1M | 62.1M |
| Current liabilities | 3.35B | 2.73B | 2.69B | 2.96B | 3.06B | 3.50B | 3.43B | 4.11B | 2.53B | 1.21B |
| Long-term debt | 7.48M | 8.25M | 205.8M | 0 | 0 | 1.28B | 1.14B | 78.0M | 297.5M | |
| Total debt | 1.20B | 1.21B | 1.43B | 1.51B | 1.64B | 3.30B | 2.94B | 324.9M | 442.1M | |
| Total liabilities | 5.31B | 4.44B | 3.63B | 3.64B | 3.70B | 5.61B | 5.29B | 4.77B | 3.42B | 1.30B |
| Shareholders' equity | 9.41B | 7.07B | 7.22B | 7.13B | 6.44B | 5.30B | 1.48B | 1.57B | 1.78B | 2.01B |
| Shares outstanding | 2.49B | 2.52B | 2.61B | 2.62B | 2.61B | 2.61B | 2.61B | 2.61B | 2.61B | 107.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2.01B | 1.39B | 151.0M | 1.35B | -202.0M | 96.7M | 772.8M | 775.8M | 939.1M | 313.6M |
| Capital spending | -862.2M | -762.6M | -979.9M | -678.0M | -209.5M | -352.8M | -507.7M | -335.2M | -292.2M | -73.3M |
| Free cash flow | 1.15B | 628.5M | -828.8M | 676.7M | -411.5M | -256.1M | 265.1M | 440.6M | 646.9M | 240.2M |
| Cash from investing | -1.33B | -1.05B | 1.09B | 68.3M | -435.5M | 529.1M | -592.9M | -472.4M | -508.4M | -65.6M |
| Cash from financing | 894.4M | -407.4M | -894.8M | -753.7M | -1.62B | 2.35B | -1.01B | 311.3M | -347.3M | -279.6M |
| Dividends paid | -390.7M | -401.5M | -419.2M | -391.3M | -391.3M | -391.3M | -912.1M | -549.1M | -549.1M | |
| Share buybacks | -74.3M | -688.0M | -289.1M | 0 | 0 | 3.12B | -121.9M | |||
| Change in cash | 1.56B | -64.1M | 348.9M | 684.5M | -2.30B | 2.92B | -832.8M | 615.1M | 83.3M | -31.7M |
Filings
All 23 filings
Cap table
Built by 6ix from Simcere Pharmaceutical Group Limited’s releases
- Common shares
- 2,556,369,618
- Fully diluted
- 2,556,369,618
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 2,556,369,618 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,556,369,618 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Felix Wang | Senior Vice President · Since at least Nov 5, 2026 |
| Goh Aik Han | Senior Vice President, Chief Medical Officer · Since at least Nov 5, 2026 |
| Ren Jinsheng | Chairman of Simcere Pharmaceutical Group · Since at least Nov 5, 2026 |
| Shen Jun | Chief Financial Officer and Secretary of the Board of Simcere Zaiming · Since at least Nov 5, 2026 |
| Tamas Oravecz | SVP & CSO of Simcere Zaiming · Since at least Nov 5, 2026 |
| Tang Renhong | Non-Executive Director of Simcere, Chairman of the Board and CEO of Simcere Zaiming · Since at least Nov 5, 2026 |
| Wang Xi | Executive Director and Vice President · Since at least Nov 5, 2026 |
| Wang Yongyu | Senior Vice President and Chief Medical Officer of Simcere Zaiming · Since at least Nov 5, 2026 |
| Wan Yushan | Executive Director and Chief Financial Officer · Since at least Nov 5, 2026 |
| Zhou Gaobo | Chief Investment Officer · Since at least Jun 12, 2026 |
Log in to ask 6ix AI your own questions about Simcere Pharmaceutical Group Limited.